Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Nov 20, 2014
Amneal Launches AG for Novo Nordisk’s ACTIVELLA®
PDF format download (opens in new window)
Nov 10, 2014
Impax Laboratories to Present at the 2014 Credit Suisse Healthcare Conference on November 11
Nov 06, 2014
Impax Submits Marketing Authorization Application to EMA for IPX066 (Carbidopa-Levodopa) Extended-Release Capsules
Nov 04, 2014
Impax's Third Quarter 2014 Revenues Increased 19% to $158 Million
Oct 30, 2014
Impax Announces R&D Reorganization Designed to Yield Process Improvements and Efficiencies
Oct 27, 2014
Amneal Execs Receive Long Island Cares Humanitarian Award
PDF format download (opens in new window)
Oct 24, 2014
Amneal‘s Candis Edwards to Present at 2014 GPhA Fall Technical Conference
PDF format download (opens in new window)
Oct 22, 2014
Impax Announces Departure of Carole Ben-Maimon, M.D., President of Global Pharmaceuticals
Oct 21, 2014
Amneal Wins Generics Bulletin “Company of the Year” Award
PDF format download (opens in new window)
Oct 09, 2014
Impax To Acquire Tower Holdings, Inc. And Lineage Therapeutics Inc.
Oct 07, 2014
Impax Laboratories to Announce Results for Third Quarter 2014 on November 4
Sep 29, 2014
Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD
Sep 23, 2014
Amneal Undertakes Major Sales & Distribution Expansion in KY
PDF format download (opens in new window)
Sep 17, 2014
Impax Pharmaceuticals Announces Extension of RYTARY™ FDA Review Date to January 9, 2015
Sep 12, 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Impax Laboratories, Inc. and Certain Officers - IPXL
Aug 15, 2014
Amneal Launches Four New Generics
PDF format download (opens in new window)
Aug 06, 2014
Impax's Second Quarter 2014 Revenues Increased 45% to $188.1 Million
Aug 04, 2014
FDA Performs Inspection of Impax's Hayward Facility
Jul 29, 2014
FDA Performs Inspection of Impax's Taiwan Facility
Jul 02, 2014
Impax Acquires Two Products from Actavis
Jul 01, 2014
Impax Laboratories to Announce Results for Second Quarter 2014 on August 6
Jun 06, 2014
Impax to Present at Goldman Sachs 35th Annual Global Healthcare Conference
May 30, 2014
NJCU to Honor Pharma Giant Chirag Patel
PDF format download (opens in new window)
May 12, 2014
Impax Laboratories to Present at Upcoming Investor Conferences
May 01, 2014
Impax Laboratories Reports First Quarter 2014 Results
Apr 21, 2014
Impax Board of Directors Appoints G. Frederick Wilkinson President and CEO
Apr 16, 2014
Impax Launches Authorized Generic RENVELA®
Apr 11, 2014
Impax Pharmaceuticals Resubmits New Drug Application for RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules (IPX066)
Apr 07, 2014
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2014 Financial Results
Apr 02, 2014
Impax Laboratories Announces the Alignment of Quality and Manufacturing Operations Under the Leadership of Jeffrey D. Nornhold
Feb 26, 2014
Impax Laboratories to Present at the Cowen and Company 34th Annual Health Care Conference
Feb 20, 2014
Impax Laboratories Reports Fourth Quarter and Full Year 2013 Results
Jan 24, 2014
Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2013 Financial Results
Jan 14, 2014
Impax Laboratories Provides Financial Outlook for 2014
Jan 10, 2014
Drugmakers to FDA: Can you speed it up? Amneal, providers paying the price of approval backlog
PDF format download (opens in new window)
Jan 09, 2014
Amneal Appoints Rochelle Fuhrmann New Chief Financial Officer
PDF format download (opens in new window)
Jan 07, 2014
Impax Laboratories to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Jan 07, 2014
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR® Pain Patch
Jan 06, 2014
Amneal Announces Launch of Esomeprazole Strontium 49.3 mg Delayed-Release Capsules Authorized Generic
PDF format download (opens in new window)

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top